ampel-logo.jpg

CHARLOTTESVILLE, VA – AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. Revealed in the peer-reviewed journal Nature’s Scientific Reports, the paper details our breakthrough machine learning approach to predict disease activity from gene data obtained from patient blood samples. The lab test, only a concept for the last few years, is now ready for development for practical use. AMPEL’s initial focus was Lupus, but the test can be used for many autoimmune or inflammatory diseases.

AMPEL’s innovative machine learning approach, which is now ready to be developed as a decision support biomarker blood test could greatly impact health care, by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely. The application of our machine learning approach could assist pharmaceutical companies in drug development and clinical trials.

hrsa-logo

Do you have an innovative idea to help solve a health issue affecting moms and kids today? Here’s your chance to make it happen! The Maternal and Child Health Bureau (MCHB), part of the U.S. Health Resources and Services Administration (HRSA), invites you to participate in our four prize-awarded Challenges with a total prize purse of $1.5 million. These competitions seek low-cost, scalable, innovative solutions that improve the health of mothers and children across the U.S.

BioTracGovernorsCitation

On behalf of Bio-Trac, Co-Founder and Director Mark Nardone received a Governor’s Citation for Bio-Trac’s 33 years of service to the scientific community, having provided hands-on training to over 17,000 scientists. At last night’s well attended Stem Cell BioPanel event at the Montgomery College Bioscience Education Center, Mr. Nardone was caught by surprise, not knowing this award was to take place. In a heartfelt address, he mentioned to the audience of scientists that it was exactly the 1 year anniversary of Dr. Roland M Nardone’s passing and how he would have been pleased by the honor but even more so to see a room full of research scientists attending an event to gain knowledge, insight and network among their peers.

agt-hiv-logo

American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use these materials to validate the patient-specific AGT103-T therapeutic manufacturing process. AGT expects AGT103-T will eliminate HIV from the body when infused back into the patient and will decrease or eliminate the need for lifelong antiretroviral treatment.

tedco-2019-422-million-logo

The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced its recent investments through the Maryland Innovation Initiative (MII). With the latest round of funding, MII’s funding count for FY19 includes 26 technology assessment grants and seven start-up investments for a total of $4.22 million. True to its technology agnostic funding history, this year the startups ranged from Cleantech to AI and Biotech.

johns-hopkins-logo

Researchers at the Johns Hopkins Kimmel Cancer Center, the Greenberg Bladder Cancer Institute, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Brady Urological Institute, and the Center for Computational Genomics at Johns Hopkins have received a $3.2 million grant from the National Institutes of Health to study new treatment options for early-stage bladder cancer.

floreo-logo

At the close of the 2019 BioHealth Capital Region Forum in April, Floreo Inc. was announced as the winner of the BioHealth Innovation’s 4th annual Crab Trap Competition and the $10,000 grand prize provided by WSGR. Floreo, Inc., which is “…using the power of virtual reality to deliver immersive, fun, and affordable lessons for children and adults with autism spectrum disorder (ASD)…”, was selected by the judges from a group of five finalists.

BHCR logo top 3 logo

Access to capital has been an ongoing challenge for biohealth companies in the BioHealth Capital Region (BCHR) and throughout the Mid Atlantic, though recent investment data suggests that capital market access is improving. “PwC/CB Insights ranks the region fourth with $944.07 million in 44 deals and Jones Lang Lasalle tallies $1.1 billion, good enough for third,” stated Rich Bendis, CEO of BioHealth Innovation (BHI), in his keynote speech at the recent The National Cancer Institute (NCI) Technology Transfer Showcase. 

Arlington-Capital-Partners-logo

Arlington Capital Partners (“Arlington” or the “Firm”), a Washington, D.C. area based private equity investment firm focused on government-regulated sectors, today announced that it has successfully raised its latest fund, Arlington Capital Partners V, L.P. (“Fund V” or the “Fund”) with total capital commitments of approximately $1.7 billion – hitting the Fund’s hard cap. The fundraise, which was significantly oversubscribed, successfully reached its final closing in three months from its launch. The Fund sourced capital commitments from a hand-selected, globally diverse group of marquis investors, including public pension funds, corporate pension funds, insurance companies, fund of funds, and foundations.

martine-rothblatt-fortune-live-media-flickr

Sometimes a Eureka moment sparks a breakthrough in innovation; other times it’s a rush to solve a crisis plaguing society — and the ones you love. That was the case for Martine Rothblatt, CEO of United Therapeutics, a Maryland-based company she founded in 1996, and former CEO of GeoStar and creator of SiriusXM Radio.

cetlin-mockv-image.jpg

If biopharma firms want to get the most out of continuous manufacturing, they must rethink their viral safety strategies. Existing strategies work well for batch-mode production, as hard-won experience attests. These strategies, however, are still being adapted to continuous-mode production, where protocols and equipment preferences are in flux.